Abiopharma

🔍 Neervannan Seshadri (Executive)

Company: Tarsus Pharmaceuticals, Inc. (TARS)

Report Date: 2026-03-17

Detailed Transactions and Holdings:

• Sold 3,125 shares of Common Stock at $69.42 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 93,979.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,610 shares of Common Stock at $68.71 per share (Direct)
  Date: 2026-03-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 90,369.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 4,589 shares of Common Stock at $67.0 per share (Direct)
  Date: 2026-03-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 85,780.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-17 | Code: H | nature_of_ownership: By daughter | shares_owned_after: 475.00 | Footnotes: F2

Footnotes:

• F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
• F2: This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.